

ProteoTech's Chief Scientific Officer, Dr. Alan Snow, to Present New Data on "Systebryl™ for the Treatment of Systemic AA Amyloidosis" at the XIIIth International Symposium on Amyloidosis, Groningen, Netherlands, May 6-10, 2012

ProteoTech Inc., April 23, 2012 announced that the Company's President & Chief Scientific Officer, Alan D. Snow, Ph.D., will give an oral presentation on Thursday May 10, 2012 at the XIII International Symposium on Amyloidosis, University Medical Center, Groningen, Netherlands. The title of Dr. Snow's presentation is: "Marked Removal and Clearance of AA Amyloid Deposits in Target Organs (Kidney, Liver and Spleen) by the Small Molecule Systebryl™ Following Oral Administration: A Potential Break-through Drug for the Treatment of Systemic AA Amyloidosis".

The talk will highlight new data demonstrating that oral treatment with ProteoTech's small molecule Systebryl™ causes a marked prevention of AA amyloid fibril formation, and a marked reduction and clearance (by 50-80%) of pre-existing AA amyloid fibril deposits in a relevant animal model of systemic AA amyloidosis. Systebryl™ has completed Phase 1a human clinical trials and in the next year, ProteoTech hopes to advance this drug candidate through Phase 2a "proof-of-concept" trials. Systemic AA amyloidosis is observed in a subset of patients with chronic inflammatory disorders and in a familial form (known as Familial Mediterranean Fever) in which insoluble amyloid deposits accumulate in vital organs (including kidney and liver) leading to organ dysfunction and failure. Systemic AA amyloidosis currently affects tens of thousands of patients world-wide with no current effective treatment. Systebryl™ is believed to be the first small molecule drug that following oral administration causes a marked reduction and clearance of pre-existing AA amyloid deposits.

About ProteoTech: ProteoTech is a private research and drug development Company located in the Seattle, WA area (Kirkland, WA) and is focused on targeting misfolded protein disorders and amyloid diseases. The Company is developing small molecule drugs for the treatment of Parkinson's disease, Alzheimer's disease, type 2 diabetes, and systemic amyloid disorders (including AA, AL and TTR amyloidoses). For more information, please see the Company website at www.proteotech.com.